Document Detail


Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.
MedLine Citation:
PMID:  24405858     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Treatment of Chronic Myeloid Leukaemia (CML) has evolved rapidly in the last 10 years. The objectives of this national consensus meeting were to describe the optimal procedures to perform at diagnosis, the most appropriate choice of tyrosine kinase inhibitor (TKI) in the first line setting, the correct monitoring procedures, the appropriate timing for resistance identification allowing a rapid TKI switch, and the future possibility of treatment discontinuation. A panel of experts in CML management were invited for a 2-day workshop. Prior to the conference, the organizing committee selected several topics and assigned them to different physicians divided in four groups. Issues discussed were (1) role of cytogenetic and molecular response monitoring in 2013; (2) frontline treatment of CML in 2013 and therapeutic objectives; (3) how to monitor response and when to change therapy after resistance or non-optimal responses; (4) possible therapy discontinuation after achievement of deep and stable molecular responses. Different national experts reviewed the literature, analyzed levels of evidence for each topic and, after extensive discussions within smaller working groups, presented their conclusions during the meeting. Each consensus aim was then evaluated by a general vote in the plenary sessions.
Authors:
Massimo Breccia; Giuliana Alimena; Michele Baccarani; Monica Bocchia; Francesco Di Raimondo; Carlo Gambacorti-Passerini; Antonella Gozzini; Enrica Morra; Fabrizio Pane; Patrizia Pregno; Giovanna Rege-Cambrin; Gianantonio Rosti; Giorgina Specchia; Paolo Vigneri; Giuseppe Saglio
Related Documents :
24529488 - Commentary: methods of evaluating lumbar and cervical fusion.
24016928 - Interaction between cardiac myocytes and fibroblasts: in vivo and in vitro.
24719888 - Evidence for the use of isoflurane as a replacement for chloral hydrate anesthesia in e...
21264708 - The boundary conditions for bohr's law: when is reacting faster than acting?
23644368 - Catheter venography for the assessment of internal jugular veins and azygous vein: posi...
24422768 - Transitioning biomarkers into the clinic.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-12-17
Journal Detail:
Title:  Critical reviews in oncology/hematology     Volume:  -     ISSN:  1879-0461     ISO Abbreviation:  Crit. Rev. Oncol. Hematol.     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2014-1-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8916049     Medline TA:  Crit Rev Oncol Hematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An update on molecular biology of thyroid cancers.
Next Document:  Characterization of two transketolases encoded on the chromosome and the plasmid pBM19 of the facult...